Illumina, Inc. ILMN
NASDAQ · Healthcare · Medical - Diagnostics & Research
$192.82
Close on Fri, 20 Nov 2026 · market value $29.2B
What the price is betting on
Priced for a lot to go rightAt $193, the price assumes revenue grows about 16% a year for five years, from $4.5B to about $8.4B by FY2030. That is about twice what analysts expect for the next two years and about 57 times the company's own last three years.
Revenue growth a year. The price figure comes from a reverse DCF at a 11% discount rate.
Track it and Parra checks each report against the path, and tells you when revenue falls behind it.
Own more than ILMN? Check up to 5 of your stocks at once, free, no account.
Both sides
Three stories, three values
Bear
$111
Base
$129
Bull
$151
Today $193
- Bear $111. Cash flow grows 5% a year for the next 5 years, slower than expected, then slows to long-run growth.
- Base $129. Cash flow grows 8% a year for the next 5 years, as analysts expect, then slows to long-run growth.
- Bull $151. Cash flow grows 11% a year for the next 5 years, faster than expected, then slows to long-run growth.
Stories set by rules from the company’s record.
Checkpoints
The revenue the price needs
- YearNeedsAnalysts expect
- FY2026$4.7B$4.6B, on the path
- FY2027$5.4B$4.9B, below the path
- FY2028$6.3B$5.3B, below the path
- FY2029$7.3B$5.8B, below the path
- FY2030$8.4B$6.1B, below the path
Each year's revenue at 16% growth from $4.5B in the 12 months to September 2026.
At a glance
Healthcare · Medical - Diagnostics & Research · listed on NASDAQ
- Revenue, FY2025
- $4.3B
- Growth, 3 years a year
- 0.3%
- Cash margin
- 21%
- Net debt
- $920M
- Shares, 3-year change
- +3.3%
- Dividend yield
- 0%
What other healthcare prices are betting on
Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.